Research Study

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Principal Investigator 
Alan I. So

Overview

Body Locations and Systems 
Prostate Cancer
ClinicalTrials.gov# 
NCT03085095
Status 
Recruiting
Study Start/End 
Nov 7, 2017 to Apr 30, 2020
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jacquie Stevenson, Research Coordinator
Phone 
604-875-4111 ext.68298
Purpose of Study 

The purpose of this study is to determine the benefit and safety of relugolix 120 mg once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (<=50 ng/dL [1.7 nmol/L] in patients with androgen-sensitive advanced prostate cancer.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.